Thompson Davis & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Thompson Davis & Co’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,153	Closed	-$6K	–	1260
2016 Q3	$6K	Buy	+1,153	New	+$6.22K	0.01%	812
2015 Q3	–	Sell	-139	Closed	-$931	–	1300
2015 Q2	$1K	Hold	139	–	–	﹤0.01%	1170
2015 Q1	$2K	Buy	+139	New	+$1.79K	﹤0.01%	1109

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Thompson Davis & Co's KERX Position: Q4 2016 in Review

Thompson Davis & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2016, closing a stake of 1,153 shares — an estimated $6K sold.

Thompson Davis & Co first reported a position in KERX in Q1 2015 and held it in 3 quarters. The position peaked at $6K in Q3 2016. 123 funds tracked by Wall St. Rank hold KERX as of Q4 2016.

Thompson Davis & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
Thompson Davis & Co sold 1,153 Keryx Biopharmaceuticals Inc shares in Q4 2016, an estimated $6K.
Thompson Davis & Co first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 3 quarters.
Thompson Davis & Co's Keryx Biopharmaceuticals Inc position peaked at $6K in Q3 2016.
123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.